135 related articles for article (PubMed ID: 31632670)
1. Growth inhibitory efficacy and anti-aromatase activity of
Telang N; Nair HB; Wong GYC
Biomed Rep; 2019 Nov; 11(5):222-229. PubMed ID: 31632670
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellandae tree.
Mukherjee B; Telang N; Wong GY
Int J Mol Med; 2009 Aug; 24(2):253-60. PubMed ID: 19578798
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
4. Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
Lui A; New J; Ogony J; Thomas S; Lewis-Wambi J
BMC Cancer; 2016 Jul; 16():487. PubMed ID: 27421652
[TBL] [Abstract][Full Text] [Related]
5. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
[TBL] [Abstract][Full Text] [Related]
6. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
7. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
8. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
9. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
[TBL] [Abstract][Full Text] [Related]
11. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
12. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer.
Telang N
Oncol Lett; 2018 Oct; 16(4):5489-5497. PubMed ID: 30214619
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Testosterone Aromatization by the Indole-3-carbinol Derivative CTet in CYP19A1-overexpressing MCF-7 Breast Cancer Cells.
De Santi M; Carloni E; Galluzzi L; Diotallevi A; Lucarini S; Magnani M; Brandi G
Anticancer Agents Med Chem; 2015; 15(7):896-904. PubMed ID: 25612679
[TBL] [Abstract][Full Text] [Related]
15. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibitory efficacy of
Telang NT; Nair HB; Wong GYC
Oncol Lett; 2019 Jun; 17(6):5261-5266. PubMed ID: 31186742
[TBL] [Abstract][Full Text] [Related]
17. The nutritional herb
Telang NT; Li G; Katdare M; Sepkovic DW; Bradlow HL; Wong GYC
Oncol Lett; 2017 Apr; 13(4):2477-2482. PubMed ID: 28454423
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
19. [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Chen HY; Liu ZH
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):423-8. PubMed ID: 24119901
[TBL] [Abstract][Full Text] [Related]
20. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]